William Benton Jones - Aug 11, 2022 Form 4 Insider Report for Corvus Pharmaceuticals, Inc. (CRVS)

Role
SVP, Pharmaceutical Development
Signature
/s/ Leiv Lea, as Attorney-in-Fact for William Benton Jones, Ph.D.
Stock symbol
CRVS
Transactions as of
Aug 11, 2022
Transactions value $
$0
Form type
4
Date filed
8/15/2022, 06:44 PM
Previous filing
Sep 13, 2021
Next filing
Dec 20, 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRVS Stock Option (Right to Buy) Award $0 +160K $0.00 160K Aug 11, 2022 Common Stock 160K $0.97 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The underlying shares subject to the option vest and become exercisable as to one-forty eighth (1/48th) of the shares subject to the option in successive, equal monthly installments measured from August 11, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

Remarks:

SVP, Pharmaceutical Development